Today ProteoNic and ModiQuest announce their collaboration on antibody expression in mammalian cell culture for use in diagnostic and therapeutic product development and manufacturing. ProteoNic will provide its expertise in construct design and protein expression optimization. ModiQuest will apply its proprietary vectors systems and expertise in high throughput production of high level expressing mammalian cell lines in combination with the UNic™ expression technology to manufacture its commercial antibodies in mammalian cell lines.
On March 30 – April 4 the “Advanced International Biotechnology Courses” will be held at the NH Leeuwenhorst Congres Centre in Noordwijkerhout and partially at the Leiden Bio Science Park, the Netherlands. In addition to sponsoring these full time, advanced professional courses, ProteoNic will give a lecture on “Upstream modification for enhanced production yield” on April 1, 2008 as part of the “Advances in Cell Culture” course. Other presenters include Xendo, Merck GmbH, Serono, BioCult and the University of Southern California.
Today ProteoNic announces it has entered into a collaboration with TNO to further commercialize and validate ProteoNic’s UNic™ expression technology in mammalian host systems. ProteoNic will provide expertise in construct design and protein expression optimization. TNO will apply this expertise and the UNic™ expression technology to manufacture commercial proteins in CHO cell lines.
Today ProteoNic BV announces the relocation of its offices at the BIO Science Park in Leiden (The Netherlands) which will take place May 1, 2007. At the new location ProteoNic will be fully equipped to carry out its R&D activities further optimizing its UNic™ expression enhancement technology and the development of other products and technologies.
ProteoNic BV was named best investors’ pitch by Tim Draper, founder and managing director of renowned American Venture Capitalist firm Draper Fischer Jurvetson. During the Holland Innovation conference in Utrecht, the Netherlands 20 selected early stage companies from the life science and high tech sectors like telecom, internet and IT were given the opportunity to pitch their proposition to Mr. Draper, Residex Venture Capital Network and Solid Ventures. The jury, chaired by Tim Draper, unanimously elected ProteoNic, one of the only two life science companies contending, as the number one pitch based on content, presentation and most promising proposition in a billion dollar market.
ARTES Biotechnology GmbH and ProteoNic BV start research collaboration Today ARTES Biotechnology GmbH, Germany, and ProteoNic B.V., the Netherlands, announce the start of their research collaboration.Both companies will join forces to investigate on the application of ProteoNic´s proprietary technology for enhancement of gene expression in the methylotrophic yeast Hansenula polymorpha, offered by ARTES.